Singapore's pharmaceutical output is likely to be flat this year, a
casualty of increasing pressure from generic drug firms. The
prediction, made by a Singapore official comes after the country
experienced a 40 per cent growth...
Novartis, the Swiss pharmaceutical giant has acquired two companies
as it aims to expand its generics drug portfolio and increase its
presence in the generics sector. The strategic move is expected to
make Novartis the world's...
Figures released by the Association of the British Pharmaceutical
Industry (ABPI) has revealed that the level of intimidation posed
by animal extremists reaches as far as the suppliers who do
business with companies involved with...
A report out today cites Novartis' pipeline of drugs to continue
its reputation of producing quality pharmaceuticals, with
treatments for cancer, age-related macular degeneration and
hypertension expected to appear within the...
Novartis has paid a US drug delivery company $10 million for an
option to an oral formulation of an injectable drug used to treat
osteoporosis that is currently the subject of litigation with Eli
The cumulative effect of patients failing to adhere to their
treatment regimens is costing the pharmaceutical industry in excess
of $30 billion a year, says a new report from Datamonitor which
proffers some solutions to the problem.
Novartis generics subsidiary Sandoz has continued its expansion
with the purchase of Canadian generic drugmaker Sabex Holdings for
$565 million (€459m) in cash, bringing in a new range of injectable
Signalling its continued commitment to the emerging economies of
the recently expanded European Union, Switzerland's Novartis has
unveiled a €70 million overall investment in a new generics
production and logistics facility in...